Bad Blood: The Amgen/J&J Feud Takes a Perilous Turn
This article was originally published in RPM Report
Executive Summary
The longstanding feud between Amgen and Johnson & Johnson is bubbling over into a battle of bundled rebates. The fight carries broad repercussions for the pricing of biopharmaceuticals. The dispute threatens to compromise the new ASP payment system under Medicare Part B before it really gets going. Industry observers threat that the next step may be more direct price controls.